NCT01287182 is a Phase 3 clinical trial of Ateronon in Atherosclerosis, sponsored by Omicron Pharmaceuticals.

Who is sponsoring NCT01287182?

NCT01287182 is sponsored by Omicron Pharmaceuticals.

What drugs are being tested in NCT01287182?

Interventions in NCT01287182: Ateronon.

What condition does NCT01287182 study?

NCT01287182 studies Atherosclerosis.

Is NCT01287182 still recruiting?

NCT01287182 is currently completed. Last updated 18 May 2013.

Last reviewed 2013-05-18 · How we verify

NCT01287182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Completed Phase 3 Last updated 18 May 2013

What this trial tests

Phase 3 trial testing Ateronon in Atherosclerosis in 100 participants. Completed in 1 December 2011.

Timeline

1 May 2011

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Omicron Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 May 2011
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	1 location across Lebanon

Drugs / interventions tested

Ateronon — full drug profile →

Conditions studied

Atherosclerosis — all drugs for Atherosclerosis →

Sponsor

Omicron Pharmaceuticals

Who can join

Adults 35 to 75, any sex, with Atherosclerosis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease
Time frame: Baseline and 3 months

Sponsor's own description

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atherosclerosis

Currently open trials in the same condition.

NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01287182 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Omicron Pharmaceuticals
Last refreshed: 18 May 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01287182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing